Renaissance Technologies
HCWB icon

Renaissance Technologies’s HCW Biologics HCWB Stock Holding History

Renaissance Technologies’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-63
Closed -$6.69K – 3605
2024
Q4 		$6.69K Buy
+63
New +$7.35K ﹤0.01% 3529
2022
Q1 		– Sell
-50
Closed -$28K – 4224
2021
Q4 		$28K Buy
+50
New +$34K ﹤0.01% 3826

Other funds holding HCWB

APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
PIM
Pullen Investment Management Bradenton, Florida $216M AUM 32.94% 1-Year Est. Return
JWCA
J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
AE Wealth Management Topeka, Kansas $18.5B AUM 19.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Renaissance Technologies's HCWB Position: Q1 2025 in Review

Renaissance Technologies sold out of HCW Biologics (HCWB) in Q1 2025, closing a stake of 63 shares — an estimated $6.69K sold.

Renaissance Technologies first reported a position in HCWB in Q4 2021 and held it in 2 quarters. The position peaked at $28K in Q4 2021. 14 funds tracked by Wall St. Rank hold HCWB as of Q1 2025.

  • Renaissance Technologies reported no remaining HCW Biologics position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 63 HCW Biologics shares in Q1 2025, an estimated $6.69K.
  • Renaissance Technologies first reported a position in HCW Biologics in Q4 2021 and held it in 2 quarters.
  • Renaissance Technologies's HCW Biologics position peaked at $28K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.